Efficacy of Recombinant Human Brain Natriuretic Peptide and Sequential Sacubitril Valsartan Sodium in the Treatment of Acute Heart Failure

LI Dan

doi:10.14033/j.cnki.cfmr.2025.04.008

Abstract：Objective:To explore the clinical efficacy of Recombinant Human Brain Natriuretic Peptide and sequential Sacubitril Valsartan Sodium in the treatment of acute heart failure.Method:A total of 97 patients with acute heart failure admitted to the Internal Medicine Department of Gejiu City Traditional Chinese Medicine Hospital from July 2023 to February 2024 were selected and randomly divided into control group(47 cases)and study group(50 cases).The control group was treated with conventional therapy combined with Recombinant Human Brain Natriuretic Peptide,while the study group was treated with conventional therapy combined with Recombinant Human Brain Natriuretic Peptide and sequential Sacubitril Valsartan Sodium.All were treated for 1 week.The indexes of the two groups were compared.Result:After treatment,the total effective rate of the control group was 76.60%,compared with 92.00%of the study group,the difference was statistically significant(P<0.05).After treatment,the levels of serum N-terminal brain natriuretic peptide precursor(NT-proBNP),cardiac troponin I(cTnI),left ventricular end-systolic diameter(LVESD)and left ventricular end-diastolic diameter(LVEDD)in both groups were decreased,and the study group was lower than that of control group,left ventricular ejection fraction(LVEF)was increased in both groups,and the study group was higher than that of control group,the differences were statistically significant(P<0.05).Conclusion:In clinical practice,the use of Recombinant Human Brain Natriuretic Peptide sequential Sacubitril Valsartan Sodium can alleviate myocardial injury,improve cardiac function,and have significant therapeutic effects in patients with acute heart failure.